Management of Heart Failure With Preserved Ejection Fraction: 2026 ACC Expert Consensus Decision Pathway

Authors, Journal, Affiliations, Type, DOI

Overview

The 2026 ACC expert consensus decision pathway updates the 2023 document for the diagnosis and management of HFpEF. It organizes care into three steps: identify possible HFpEF from symptoms and signs, exclude noncardiac and cardiac mimics, and implement optimal medical therapy alongside nonpharmacologic management and comorbidity control. The central therapeutic change is the establishment of an SGLT2 inhibitor plus a nonsteroidal mineralocorticoid receptor antagonist as foundational therapy, with incretin-based therapy for obesity-phenotype HFpEF, ARNI for selected patients, and ARB when ARNI is not feasible. The pathway also emphasizes diagnostic scoring systems, the limitations of natriuretic peptides in obesity, and the cardiovascular-kidney-metabolic framework.

Keywords

HFpEF, expert consensus decision pathway, SGLT2 inhibitors, finerenone, mineralocorticoid receptor antagonists, semaglutide, tirzepatide, ARNI, obesity, cardiovascular-kidney-metabolic syndrome

Key Takeaways

Introduction

Assumptions and Definitions

Diagnosis

HFpEF Mimics

Sex-Specific Considerations

Optimal Medical Therapy

Nonpharmacologic Management

Comorbidities

Conclusion

Limitations of the Document

Key Concepts Mentioned

Key Entities Mentioned

Wiki Pages Updated